Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,815 across all filing types
Latest filing 2025-06-23 Transaction in Own Shar…
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Transaction in Own Shares 2025
Transaction in Own Shares Classification · 1% confidence The document is titled "Transactions in Connection with Share Buy-back Program" and details the number of shares repurchased by the company (Genmab A/S) during a specific period (June 16 to June 20, 2025) under an existing buy-back program. This activity directly relates to the company managing its own stock, which falls under the definition of 'Transaction in Own Shares'. The document is a company announcement detailing these transactions, not just an announcement that a report is forthcoming (which would suggest RPA or RNS). Therefore, the most specific classification is POS (Transaction in Own Shares).
2025-06-23 English
6-K
Foreign Filer Report
2025-06-18 English
Capital/Financing Update 2025
Capital/Financing Update Classification · 1% confidence The document is a 'Company Announcement' detailing a 'Capital Increase in Genmab as a Result of Employee Warrant Exercise'. It specifies the number of shares issued, the subscription prices, the total proceeds (approximately DKK 33.3 million), and the resulting total share capital. This content directly relates to changes in the company's capital structure due to financing/issuance activities. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). Although it involves share issuance, the primary focus is the capital change resulting from warrant exercise, which is a financing event, rather than a general share repurchase (POS) or a general share issue announcement (SHA). Given the specific nature of the capital change, CAP is the most precise fit.
2025-06-18 English
Share Issue/Capital Change 2025
Share Issue/Capital Change Classification · 1% confidence The document is a 'Company Announcement' detailing a specific corporate action: a 'Capital Increase in Genmab as a Result of Employee Warrant Exercise'. This action involves the issuance of new shares and an increase in share capital, resulting in proceeds for the company. This directly relates to changes in the company's capital structure and financing activities. Based on the definitions, the most appropriate category is 'Capital/Financing Update' (CAP). It is not an earnings release (ER), a full annual report (10-K), or a general regulatory filing (RNS), as it describes a specific, material financial/capital event.
2025-06-18 English
Regulatory Filings 2025
Regulatory Filings
2025-06-17 English
6-K
Foreign Filer Report
2025-06-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.